Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Procarbazine-Free Escalated Beacopdac in Frontline Therapy of Advanced Hodgkin Lymphoma Reduces Red Cell Transfusion Requirements and May Shorten Time to Menstrual Period Recovery Compared to Escalated Beacopp and Appears to be As Efficacious

Blood (2019) 134 (Supplement_1): 1564.

https://doi.org/10.1182/blood-2019-125256

Published: 2019

Journal Articles

Effectiveness of End of Therapy PET Based Deauville Scoring in Predicting Outcomes in Hodgkin's Lymphoma: A Real-World Experience

Nikita Mehra, MD DM, Prasanth Ganesan, MD DM, Venkatraman Radhakrishnan, MD DM, Trivadi S Ganesan, MD DM, Manikandan Dhanushkodi, MD DM, Shirley Sundersingh, MD PhD, S Krupa Shankar, MD DM, Jayachandran P K, MD DM, Krishnarathnam Kannan, MD, Carthikeyan S M, MD, Tenali Gnana Sagar, MD

Blood (2018) 132 (Supplement 1): 5921.

https://doi.org/10.1182/blood-2018-99-119176

Published: 2018

Journal Articles

Metabolic Tumor Volume and Soluble Cytokines Levels in Newly Diagnosed Hodgkin Lymphoma: What It Brings into the Staging Precision?

VIT K Prochazka, MD, Lenka Henzlova, MD, Marie Lukasova, MD, Veronika Hanackova, MD, Eva Kriegova, Dr, assoc prof, Zuzana Mikulkova, Dr, Gabriela Gabcova, Dr, Jiri Minarik, MD PhD, Alice Sýkorová, MD PhD, Eva Krcalova, MD, Jiri Dolezal, MD assoc prof, Pavel Koranda, MD assoc prof, Tomas Papajik, MD prof

Blood (2018) 132 (Supplement 1): 2933.

https://doi.org/10.1182/blood-2018-99-115150

Published: 2018

Journal Articles

Outcomes within Five Years from Diagnosis in Pediatric Hodgkin Lymphoma Patients Following Contemporary Therapy

Karen E Effinger, MD MS, John Bergsagel, MD, Taylor Lawrence, Frank G Keller, MD, Rebecca Williamson Lewis, MPH, Lillian Meacham, MD, Ann Mertens, PhD, Sharon M. Castellino, MD MSc

Blood (2017) 130 (Supplement 1): 3466.

https://doi.org/10.1182/blood.V130.Suppl_1.3466.3466

Published: 2017

Journal Articles

Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): Clinical Features, Treatment, and Outcome. a Single Institution Result of 145 Patients from the Middle East

Saad Akhtar, MD, Amani Al-Kofide, MD, Nasir Bakshi, MD, Mohammed Shamayel, MD, Yasser Khafaga, MD, Suleimman Al-Sweedan, MD, Tusneem Elhassan, MSc, M S Rauf, MD, Irfan Maghfoor, MD

Blood (2017) 130 (Supplement 1): 2794.

https://doi.org/10.1182/blood.V130.Suppl_1.2794.2794

Published: 2017

Journal Articles

Suicide in European Hodgkin Lymphoma Patients

Austin Kim, MD, Andreas Engert, MD, Helen Gorgen, Louise Maranda, PhD, Ann S LaCasce, MD, Sven Borchmann, MD

Blood (2016) 128 (22): 2995.

https://doi.org/10.1182/blood.V128.22.2995.2995

Published: 2016

Journal Articles

Risk Adapted Treatment in Childhood Hodgkin's Lymphoma: Outcome and Changing Epidemiologic Features in 25 Years

Rejin Kebudi, MD Prof, Sema Bay Buyukkapu, MD, Omer Gorgun, MD, Fulya Yaman Agaoglu, MD, Bulent Zulfikar, MD, Inci Ayan, MD, Ayca Iribas, MD, Dizdar Yavuz, MD, Oner Dogan, MD, Emin Darendeliler, MD

Blood (2016) 128 (22): 4158.

https://doi.org/10.1182/blood.V128.22.4158.4158

Published: 2016

Journal Articles

A Longitudinal Definition of the Value of Cancer Drugs

Ohad Oren, MD, David H. Henry, MD

Blood (2016) 128 (22): 1185.

https://doi.org/10.1182/blood.V128.22.1185.1185

Published: 2016

Journal Articles

Nodular Lymphocyte Predominant Hodgkin Lymphoma. Experience in a Single Institution in Argentina

Elizabeth M Alfaro, MD, Cristian G Sanchez La Rosa, MD, Myriam Guitter, MD, Natalia Millan, MD, Andrea Montanari, MD, Laura Galluzzo, MD, Maria Sara Felice, MD PhD, Pedro Zubizarreta, MD

Blood (2016) 128 (22): 5361.

https://doi.org/10.1182/blood.V128.22.5361.5361

Published: 2016

Journal Articles

Beacoppescalated Followed By Radiotherapy of Initial Bulk or Residual Disease in Advanced Stage Hodgkin Lymphoma: Long-Term Follow up of the HD9 and HD12 Trials of the German Hodgkin Study Group

Stefanie Kreissl, MD, Bastian von Tresckow, MD, Helen Goergen, PhD, Heinz Haverkamp, Stephanie Sasse, MD, Volker Diehl, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2016) 128 (22): 923.

https://doi.org/10.1182/blood.V128.22.923.923

Published: 2016

Journal Articles

An Adjustable Markov Model to Project Life Expectancy (LE) for Early Stage Favorable Risk Hodgkin Lymphoma Patients Treated with Contemporary Therapy

Michael J. Kelly, MD MPH, MS, Susan K Parsons, MDMRP, David C. Hodgson, MD, Joshua T Cohen, PhD, Jennifer M Yeh, MD PhD, Jeremy S. Abramson, MD, Debra L. Friedman, MD MS, Tara O Henderson, MDMPH, Peter W Johnson, MD, Stephen G Pauker, MD, John M. Raemaekers, MD PhD, Jane N. Winter, MD, Kara M. Kelly, MD, Ralph M. Meyer, MD, Sharon M Castellino, MD, Andrew M. Evens, DO, MSc

Blood (2015) 126 (23): 2635.

https://doi.org/10.1182/blood.V126.23.2635.2635

Published: 2015

Journal Articles

Outcome of Patients with Hodgkin Lymphoma transformed from Chronic Lymphocytic Leukemia

Heidi Mocikova, MD, PhD, Jana Markova, MD, Lubica Gaherova, MD, Lukas Smolej, MD, PhD, Assoc.Prof., Martin Simkovic, MD, Tomas Kozak, MD, PhD, Prof.

Blood (2015) 126 (23): 5298.

https://doi.org/10.1182/blood.V126.23.5298.5298

Published: 2015

Journal Articles

Low Hodgkin/Reed-Sternberg Cell Density Assessed with Automated Image Analysis Is a Poor Prognostic Factor in Classic Hodgkin Lymphoma Patients

Vit Prochazka, MD PhD ass. prof., Tereza Dyskova, Dr., Zuzana Prouzova, MD, Tomas Papajik, MD PhD prof., Jiri Minarik, MD PhD, Juraj Duras, MD, Jozef Michalka, MD, Alice Sykorova, MD PhD, Peter Mikula, MD, Ludek Raida, MD PhD, Eva Kriegova, Dr., PhD

Blood (2015) 126 (23): 4999.

https://doi.org/10.1182/blood.V126.23.4999.4999

Published: 2015

Journal Articles

Long-Term Follow-up Analysis of HD2000 Trial Comparing ABVD Versus BEACOPP Versus Copp/EBV/CAD in Patients with Newly Diagnosed Advanced-Stage Hodgkin's Lymphoma: A Study from the Fondazione Italiana Linfomi

Francesco Merli, MD, Stefano Luminari, MD, Caterina Mammi, PhD, Nicola Cascavilla, MD, Alessia Bari, MD, Caterina Stelitano, MD, Renato Scalone, MD, Luca Baldini, Prof, Francesco Angrilli, MD, Giuseppe Polimeno, MD, Paolo G Gobbi, Prof, Giulia Cervetti, MD, Fiorella Ilariucci, MD, Alessia Ruffini, Luigi Marcheselli, Massimo Federico, MD

Blood (2014) 124 (21): 499.

https://doi.org/10.1182/blood.V124.21.499.499

Published: 2014

Journal Articles

Combined Modality Approach for Early Stage Unfavorable Hodgkin Lymphoma- Can We Avoid Radiation Therapy Based on Interim PET Imaging?

Van T Nguyen, MD, Judy P Tsai, MD, John P Greer, MD, David S Morgan, MD, Nishitha M Reddy, M.B.B.S.

Blood (2014) 124 (21): 5430.

https://doi.org/10.1182/blood.V124.21.5430.5430

Published: 2014

Journal Articles

Systematic Review and Individual Patient Data Meta-Analysis Of Treatment-Related Risk Of Secondary Malignant Neoplasms After Hodgkin Lymphoma

Jeremy Franklin, PhD, Dennis A. Eichenauer, MD, Ingrid Becker, MSc, Andreas Engert, MD

Blood (2013) 122 (21): 1753.

https://doi.org/10.1182/blood.V122.21.1753.1753

Published: 2013

Journal Articles

Cerebral Venous Thrombosis in Adolescents and Young Adults with Classical Hodgkin Lymphoma

Poornima Kumar, MBBS, Rebekah Ahmed, MBBS, Renu Riat, MBBS, Kirit M Ardeshna, MD, Stephen Daw, MBChb

Blood (2012) 120 (21): 4784.

https://doi.org/10.1182/blood.V120.21.4784.4784

Published: 2012

Journal Articles

Chemoresistance Can Be Reliably Overcome with High-Dose Therapy and Autologous Stem Cell Transplantation (HDT/ASCT) for Relapsed and Refractory Hodgkin's Lymphoma

Alina S. Gerrie, MD, FRCPC, Maryse M. Power, MD, FRCPath, Kerry J. Savage, MD MSc, John D. Shepherd, MD, FRCPC, Joseph M. Connors, MD

Blood (2011) 118 (21): 2022.

https://doi.org/10.1182/blood.V118.21.2022.2022

Published: 2011

Journal Articles

Heme Oxygenase 1-Induced Resistance to Imatinib In Chronic Myelogenous Leukemia Cells

Daniele Tibullo, Ignazio Barbagallo, Antonio Branca, Cesarina Giallongo, Piera La Cava, Giovanni Li Volti, Giuseppe A Palumbo, MD, Roberto Motterlini, Sr., Angelo Vanella, Sr., Francesco Di Raimondo, MD

Blood (2011) 118 (21): 4410.

https://doi.org/10.1182/blood.V118.21.4410.4410

Published: 2011

Journal Articles

BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group

Kara M. Kelly, Richard Sposto, Raymond Hutchinson, Vickie Massey, Kathleen McCarten, Sherrie Perkins, Mark Lones, Doojduen Villaluna, Michael Weiner

Blood (2011) 117 (9): 2596–2603.

https://doi.org/10.1182/blood-2010-05-285379

Published: 2011

NARROW

Procarbazine-Free Escalated Beacopdac in Frontline Therapy of Advanced Hodgkin Lymphoma Reduces Red Cell Transfusion Requirements and May Shorten Time to Menstrual Period Recovery Compared to Escalated Beacopp and Appears to be As Efficacious

Effectiveness of End of Therapy PET Based Deauville Scoring in Predicting Outcomes in Hodgkin's Lymphoma: A Real-World Experience

Metabolic Tumor Volume and Soluble Cytokines Levels in Newly Diagnosed Hodgkin Lymphoma: What It Brings into the Staging Precision?

Outcomes within Five Years from Diagnosis in Pediatric Hodgkin Lymphoma Patients Following Contemporary Therapy

Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): Clinical Features, Treatment, and Outcome. a Single Institution Result of 145 Patients from the Middle East

Suicide in European Hodgkin Lymphoma Patients

Risk Adapted Treatment in Childhood Hodgkin's Lymphoma: Outcome and Changing Epidemiologic Features in 25 Years

A Longitudinal Definition of the Value of Cancer Drugs

Nodular Lymphocyte Predominant Hodgkin Lymphoma. Experience in a Single Institution in Argentina

Beacoppescalated Followed By Radiotherapy of Initial Bulk or Residual Disease in Advanced Stage Hodgkin Lymphoma: Long-Term Follow up of the HD9 and HD12 Trials of the German Hodgkin Study Group

An Adjustable Markov Model to Project Life Expectancy (LE) for Early Stage Favorable Risk Hodgkin Lymphoma Patients Treated with Contemporary Therapy

Outcome of Patients with Hodgkin Lymphoma transformed from Chronic Lymphocytic Leukemia

Low Hodgkin/Reed-Sternberg Cell Density Assessed with Automated Image Analysis Is a Poor Prognostic Factor in Classic Hodgkin Lymphoma Patients

Long-Term Follow-up Analysis of HD2000 Trial Comparing ABVD Versus BEACOPP Versus Copp/EBV/CAD in Patients with Newly Diagnosed Advanced-Stage Hodgkin's Lymphoma: A Study from the Fondazione Italiana Linfomi

Combined Modality Approach for Early Stage Unfavorable Hodgkin Lymphoma- Can We Avoid Radiation Therapy Based on Interim PET Imaging?

Systematic Review and Individual Patient Data Meta-Analysis Of Treatment-Related Risk Of Secondary Malignant Neoplasms After Hodgkin Lymphoma

Cerebral Venous Thrombosis in Adolescents and Young Adults with Classical Hodgkin Lymphoma

Chemoresistance Can Be Reliably Overcome with High-Dose Therapy and Autologous Stem Cell Transplantation (HDT/ASCT) for Relapsed and Refractory Hodgkin's Lymphoma

Heme Oxygenase 1-Induced Resistance to Imatinib In Chronic Myelogenous Leukemia Cells

BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only